ArticleFrontiers in microbiology2021
Identification and Characterization of the CRISPR/Cas System in
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Genetic modification of intractable bacterial clones by heat shock-facilitated phage transduction.Cell reports methods · 2026Article
- Advancements in CRISPR-Cas Systems for Genome Editing towards Eradication of Human Microbial Pathogens.Molecular biotechnology · 2026Review
- CRISPR1-mediated virulence and erythromycin resistance stabilization drives regional dominance ofFrontiers in cellular and infection microbiology · 2026Article
- Genomic typing, antimicrobial resistance gene, virulence factor and plasmid replicon database for the important pathogenic bacteria Staphylococcus aureus.BMC genomic data · 2025Article
- Prevalence and genomic insights into type III-A CRISPR-Cas system acquisition in globalFrontiers in cellular and infection microbiology · 2025Article
- Controllable self-cleaning FET self-assembled RNA-cleaving DNAzyme based DNA nanotree for culture-free Staphylococcus aureus detection.Journal of nanobiotechnology · 2024Article
- Exploring the Interplay of the CRISPR-CAS System with Antibiotic Resistance inMedicina (Kaunas, Lithuania) · 2024Article
- A bioinformatic approach to identify confirmed and probable CRISPR-Cas systems in theFrontiers in microbiology · 2024Article
- Correlation between CRISPR Loci Diversity in Three Enterobacterial Taxa.International journal of molecular sciences · 2022Article
- Whole-Genome Analysis ofFoods (Basel, Switzerland) · 2022Article
- Understanding the Mechanisms That Drive Phage Resistance in Staphylococci to Prevent Phage Therapy Failure.Viruses · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The CRISPR-Cas [clustered regularly interspaced short palindromic repeats and the CRISPR-associated genes (Cas)] system provides defense mechanisms in bacteria and archaea vs. mobile genetic elements (MGEs), such as plasmids and bacteriophages, which can either be harmful or add sequences that can provide virulence or antibiotic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.